European Heart Journal vs Diabetes Care: Which Journal Should You Choose?

EHJ asks whether the paper matters across cardiology. Diabetes Care asks whether the paper matters across diabetes practice.

That sounds obvious, but it's exactly where many cardiometabolic submissions go wrong.

EHJ's editorial guidance are explicit about broad cardiovascular importance, methodological rigor, and practice consequence. Diabetes Care's editorial guidance emphasize clinically useful diabetes evidence, management implications, and research that helps diabetes clinicians do something better.

So if the paper is primarily about cardiovascular events, cardiovascular prevention, or field-wide risk interpretation, EHJ is stronger. If the paper is primarily about diabetes treatment, diabetes management, implementation, or diabetes-specific decision-making, Diabetes Care is usually the cleaner fit.

EHJ wins when the manuscript is fundamentally cardiovascular.

That usually means:

• cardiovascular outcomes are the real headline
• cardiologists are the main audience
• the paper has implications that go beyond diabetes specialists
• the result belongs in a general cardiology conversation

Examples:

• cardiovascular outcome analyses where diabetes is the key population but not the whole editorial identity
• risk-stratification work that should influence cardiovascular care broadly
• cardiometabolic prevention studies where the practical audience includes general cardiologists, not only diabetes clinicians

EHJ's editorial guidance repeatedly reinforces that the journal wants broad cardiology consequence, not just a strong subspecialty dataset.

Diabetes Care wins when the paper is fundamentally about diabetes care.

That includes:

• studies on diabetes management, treatment pathways, or implementation
• papers about diabetes populations where the practical question is how diabetes clinicians should change care
• work on diabetes risk, complications, or therapeutics where the real audience is endocrinology and diabetes practice
• clinically useful studies with direct implications for patient management in diabetes

Diabetes Care's editorial guidance is especially useful here. It keeps focusing on clinical utility, patient-facing consequence, and the need to show why the result changes diabetes care rather than merely describing an interesting association.

EHJ is more demanding about field breadth

Even a strong diabetes-related paper may still be too practice-specific or too population-bound for EHJ if it doesn't clearly matter across cardiology.

Diabetes Care is more comfortable with diabetes-first framing

That matters because many important cardiometabolic studies are still best told through the lens of diabetes populations, diabetes treatment, and diabetes clinician decisions.

EHJ wants practice consequence for cardiologists

EHJ's editorial guidance is explicit that the journal wants authors to explain how findings could change cardiovascular practice. If that argument feels secondary, the fit weakens.

Diabetes Care wants patient-management consequence for diabetes clinicians

Diabetes Care's editorial guidance repeatedly focuses on whether the paper helps clinicians diagnose, manage, or treat diabetes more effectively. If the manuscript can't answer that question cleanly, it becomes a weaker target there.

• the manuscript is fundamentally cardiovascular
• general cardiologists are the real audience
• the main implication is about cardiovascular prevention, outcomes, or interpretation
• the diabetes population is central, but the message still belongs to cardiology

That's the EHJ lane.

• the manuscript is fundamentally about diabetes care
• diabetes clinicians are the real audience
• the paper changes diabetes management, patient selection, or clinical decision-making
• the study becomes stronger when written as a diabetes-practice paper

That's the Diabetes Care lane.

Cardiovascular outcomes in diabetes

These can go either way. If the result should change broad cardiovascular thinking, EHJ gets stronger. If the result mainly changes diabetes management or therapeutic choice within diabetes populations, Diabetes Care often wins.

Cardiometabolic prevention studies

Again, the deciding factor is audience. If the practical reader is a cardiologist managing risk, EHJ makes more sense. If the practical reader is a diabetes clinician managing a diabetic population, Diabetes Care often fits better.

Drug-effect and implementation papers

These often belong in Diabetes Care if the real value is how diabetes clinicians should prescribe, monitor, or manage patients. They become EHJ papers only when the cardiovascular consequence is broad enough to reach a larger cardiology audience.

This is a real and sensible cascade.

A paper rejected by EHJ because it's too diabetes-defined can still be a strong Diabetes Care paper if:

• the study is clinically useful
• the evidence is solid
• the main audience is diabetes care

The reverse route can also happen, but less often. A paper rejected by Diabetes Care because it isn't sufficiently diabetes-practice focused doesn't automatically become an EHJ paper unless the cardiovascular consequence is genuinely broad.

EHJ punishes narrow practice framing

If the whole story only makes sense as a diabetes-management paper, EHJ becomes much less realistic.

Diabetes Care punishes weak clinical utility

The journal's editorial guidance is clear that the journal wants actionable clinical relevance. Interesting data without a meaningful effect on care is a weak fit.

EHJ punishes cardiometabolic papers that never become field-wide cardiology papers

The paper has to cross that threshold, not just touch it.

Diabetes Care punishes manuscripts that borrow a diabetes population but aren't really about diabetes care

If the paper mainly wants the diabetes audience for convenience rather than because it belongs there, that usually shows.

A strong EHJ first page makes the cardiovascular consequence obvious immediately, even if the cohort is a diabetes population.

A strong Diabetes Care first page makes the diabetes-care consequence obvious immediately, even if cardiovascular endpoints are central.

That's often the fastest way to test the fit.

Finish one of these sentences:

• "this changes what cardiologists should do or how they interpret cardiovascular risk" points toward European Heart Journal
• "this changes how diabetes clinicians should manage patients" points toward Diabetes Care

Whichever sentence sounds truer usually reveals the better first target.

Send to European Heart Journal first if:

1. the manuscript is fundamentally cardiovascular
2. cardiologists are the main audience
3. the paper has broad cardiovascular implications
4. diabetes context supports the story, but doesn't define it

Send to Diabetes Care first if:

1. the manuscript is fundamentally about diabetes care
2. diabetes clinicians are the main audience
3. the practical consequence is in diabetes management
4. cardiovascular outcomes matter, but the core message still sits inside diabetes care